Cargando…
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells
The oncogenic Pim2 kinase is overexpressed in several haematological malignancies, such as multiple myeloma and acute myeloid leukaemia (AML), and constitutes a strong therapeutic target candidate. Like other Pim kinases, Pim2 is constitutively active and is believed to be essentially regulated thro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672348/ https://www.ncbi.nlm.nih.gov/pubmed/26500282 http://dx.doi.org/10.1042/BSR20150217 |
_version_ | 1782404553700802560 |
---|---|
author | Adam, Kévin Lambert, Mireille Lestang, Elsa Champenois, Gabriel Dusanter-Fourt, Isabelle Tamburini, Jérôme Bouscary, Didier Lacombe, Catherine Zermati, Yael Mayeux, Patrick |
author_facet | Adam, Kévin Lambert, Mireille Lestang, Elsa Champenois, Gabriel Dusanter-Fourt, Isabelle Tamburini, Jérôme Bouscary, Didier Lacombe, Catherine Zermati, Yael Mayeux, Patrick |
author_sort | Adam, Kévin |
collection | PubMed |
description | The oncogenic Pim2 kinase is overexpressed in several haematological malignancies, such as multiple myeloma and acute myeloid leukaemia (AML), and constitutes a strong therapeutic target candidate. Like other Pim kinases, Pim2 is constitutively active and is believed to be essentially regulated through its accumulation. We show that in leukaemic cells, the three Pim2 isoforms have dramatically short half-lives although the longer isoform is significantly more stable than the shorter isoforms. All isoforms present a cytoplasmic localization and their degradation was neither modified by broad-spectrum kinase or phosphatase inhibitors such as staurosporine or okadaic acid nor by specific inhibition of several intracellular signalling pathways including Erk, Akt and mTORC1. Pim2 degradation was inhibited by proteasome inhibitors but Pim2 ubiquitination was not detected even by blocking both proteasome activity and protein de-ubiquitinases (DUBs). Moreover, Pyr41, an ubiquitin-activating enzyme (E1) inhibitor, did not stabilize Pim2, strongly suggesting that Pim2 was degraded by the proteasome without ubiquitination. In agreement, we observed that purified 20S proteasome particles could degrade Pim2 molecule in vitro. Pim2 mRNA accumulation in UT7 cells was controlled by erythropoietin (Epo) through STAT5 transcription factors. In contrast, the translation of Pim2 mRNA was not regulated by mTORC1. Overall, our results suggest that Pim2 is only controlled by its mRNA accumulation level. Catalytically active Pim2 accumulated in proteasome inhibitor-treated myeloma cells. We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma. |
format | Online Article Text |
id | pubmed-4672348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46723482015-12-17 Control of Pim2 kinase stability and expression in transformed human haematopoietic cells Adam, Kévin Lambert, Mireille Lestang, Elsa Champenois, Gabriel Dusanter-Fourt, Isabelle Tamburini, Jérôme Bouscary, Didier Lacombe, Catherine Zermati, Yael Mayeux, Patrick Biosci Rep Original Papers The oncogenic Pim2 kinase is overexpressed in several haematological malignancies, such as multiple myeloma and acute myeloid leukaemia (AML), and constitutes a strong therapeutic target candidate. Like other Pim kinases, Pim2 is constitutively active and is believed to be essentially regulated through its accumulation. We show that in leukaemic cells, the three Pim2 isoforms have dramatically short half-lives although the longer isoform is significantly more stable than the shorter isoforms. All isoforms present a cytoplasmic localization and their degradation was neither modified by broad-spectrum kinase or phosphatase inhibitors such as staurosporine or okadaic acid nor by specific inhibition of several intracellular signalling pathways including Erk, Akt and mTORC1. Pim2 degradation was inhibited by proteasome inhibitors but Pim2 ubiquitination was not detected even by blocking both proteasome activity and protein de-ubiquitinases (DUBs). Moreover, Pyr41, an ubiquitin-activating enzyme (E1) inhibitor, did not stabilize Pim2, strongly suggesting that Pim2 was degraded by the proteasome without ubiquitination. In agreement, we observed that purified 20S proteasome particles could degrade Pim2 molecule in vitro. Pim2 mRNA accumulation in UT7 cells was controlled by erythropoietin (Epo) through STAT5 transcription factors. In contrast, the translation of Pim2 mRNA was not regulated by mTORC1. Overall, our results suggest that Pim2 is only controlled by its mRNA accumulation level. Catalytically active Pim2 accumulated in proteasome inhibitor-treated myeloma cells. We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma. Portland Press Ltd. 2015-12-08 /pmc/articles/PMC4672348/ /pubmed/26500282 http://dx.doi.org/10.1042/BSR20150217 Text en © 2015 Authors http://creativecommons.org/licenses/by/3.0/ This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0 (http://creativecommons.org/licenses/by/3.0/) . |
spellingShingle | Original Papers Adam, Kévin Lambert, Mireille Lestang, Elsa Champenois, Gabriel Dusanter-Fourt, Isabelle Tamburini, Jérôme Bouscary, Didier Lacombe, Catherine Zermati, Yael Mayeux, Patrick Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title_full | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title_fullStr | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title_full_unstemmed | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title_short | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
title_sort | control of pim2 kinase stability and expression in transformed human haematopoietic cells |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672348/ https://www.ncbi.nlm.nih.gov/pubmed/26500282 http://dx.doi.org/10.1042/BSR20150217 |
work_keys_str_mv | AT adamkevin controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT lambertmireille controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT lestangelsa controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT champenoisgabriel controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT dusanterfourtisabelle controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT tamburinijerome controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT bouscarydidier controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT lacombecatherine controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT zermatiyael controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells AT mayeuxpatrick controlofpim2kinasestabilityandexpressionintransformedhumanhaematopoieticcells |